# First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

> **NCT01646450** · PHASE4 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 35 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT01646450
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2015-12
- **Final completion:** 2016-04
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2015-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646450, "First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01646450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*